Athira Pharma, Inc.
ATHA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $243 | $200 | $243 | $0 |
| Gross Profit | -$243 | -$200 | -$243 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,582 | $3,661 | $4,302 | $9,370 |
| G&A Expenses | $4,049 | $3,630 | $5,234 | $6,196 |
| SG&A Expenses | $4,049 | $3,630 | $5,234 | $6,196 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$200 | -$243 | $0 |
| Operating Expenses | $6,631 | $7,091 | $9,293 | $15,566 |
| Operating Income | -$6,874 | -$7,291 | -$9,536 | -$15,566 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $263 | $325 | $393 | $563 |
| Pre-Tax Income | -$6,611 | -$6,966 | -$9,143 | -$15,003 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6,611 | -$6,966 | -$9,143 | -$15,003 |
| % Margin | – | – | – | – |
| EPS | -1.68 | -1.78 | -2.3 | -3.9 |
| % Growth | 5.6% | 22.6% | 41% | – |
| EPS Diluted | -1.68 | -1.78 | -2.3 | -3.9 |
| Weighted Avg Shares Out | 3,944 | 3,909 | 3,904 | 3,848 |
| Weighted Avg Shares Out Dil | 3,944 | 3,909 | 3,904 | 3,848 |
| Supplemental Information | – | – | – | – |
| Interest Income | $263 | $325 | $393 | $563 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $108 | $200 | $243 | $243 |
| EBITDA | -$6,503 | -$6,766 | -$8,900 | -$15,323 |
| % Margin | – | – | – | – |